Tevimbra (tislelizumab-jsgr) — Medica
Gastric or Gastroesophageal Junction Adenocarcinoma
Initial criteria
- age ≥ 18 years
- unresectable locally advanced, recurrent, or metastatic HER2-negative disease
- tumor expresses PD-L1 ≥ 1%
- used first-line
- used in combination with platinum and fluoropyrimidine-based chemotherapy
- prescribed by or in consultation with an oncologist
Approval duration
1 year